Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Early detection of the PAX3-FOXO1 fusion gene in circulating tumor-derived DNA in a case of alveolar rhabdomyosarcoma.

Eguchi-Ishimae M, Tezuka M, Kokeguchi T, Nagai K, Moritani K, Yonezawa S, Tauchi H, Tokuda K, Ishida Y, Ishii E, Eguchi M.

Genes Chromosomes Cancer. 2019 Feb 10. doi: 10.1002/gcc.22734. [Epub ahead of print]

PMID:
30739374
2.

SAMD5 mRNA was overexpressed in prostate cancer and can predict biochemical recurrence after radical prostatectomy.

Li F, Xu Y, Liu RL.

Int Urol Nephrol. 2019 Feb 9. doi: 10.1007/s11255-019-02096-3. [Epub ahead of print]

PMID:
30739268
3.

Comparative assessment of prognostic outcomes between first-generation antiandrogens and novel androgen-receptor-axis-targeted agents in patients with non-metastatic castration-resistant prostate cancer.

Miyake H, Matsushita Y, Watanabe H, Tamura K, Motoyama D, Ito T, Sugiyama T, Otsuka A.

Int J Clin Oncol. 2019 Feb 9. doi: 10.1007/s10147-019-01412-2. [Epub ahead of print]

PMID:
30739263
4.

Healthy behavioral choices and cancer screening in persons living with HIV/AIDS are different by sex and years since HIV diagnosis.

Wijayabahu AT, Zhou Z, Cook RL, Brumback B, Ennis N, Yaghjyan L.

Cancer Causes Control. 2019 Feb 9. doi: 10.1007/s10552-019-1135-3. [Epub ahead of print]

PMID:
30739240
5.

Combination therapies in prostate cancer: proceed with caution.

Spratt DE.

Lancet Oncol. 2019 Feb 6. pii: S1470-2045(18)30929-X. doi: 10.1016/S1470-2045(18)30929-X. [Epub ahead of print] No abstract available.

PMID:
30738781
6.

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.

Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, Boegemann M, Matveev V, Piulats JM, Zucca LE, Karyakin O, Kimura G, Matsubara N, Nahas WC, Nolè F, Rosenbaum E, Heidenreich A, Kakehi Y, Zhang A, Krissel H, Teufel M, Shen J, Wagner V, Higano C.

Lancet Oncol. 2019 Feb 6. pii: S1470-2045(18)30860-X. doi: 10.1016/S1470-2045(18)30860-X. [Epub ahead of print]

PMID:
30738780
7.

Moderate hypofractionation and stereotactic body radiation therapy in the treatment of prostate cancer.

Beckta JM, Nosrati JD, Yu JB.

Urol Oncol. 2019 Feb 6. pii: S1078-1439(19)30016-X. doi: 10.1016/j.urolonc.2019.01.015. [Epub ahead of print] Review.

PMID:
30738746
9.

Re: Timu J. Murtola, Hemo Syvälä, Teemu Tolonen, et al. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial. Eur Urol 2018;74:697-701.

Kim JH, Chung BI.

Eur Urol. 2019 Feb 6. pii: S0302-2838(19)30088-0. doi: 10.1016/j.eururo.2019.01.042. [Epub ahead of print] No abstract available.

PMID:
30738708
10.

Mortality in Incident Maintenance Dialysis Patients Versus Incident Solid Organ Cancer Patients: A Population-Based Cohort.

Naylor KL, Kim SJ, McArthur E, Garg AX, McCallum MK, Knoll GA.

Am J Kidney Dis. 2019 Jan 28. pii: S0272-6386(18)31126-0. doi: 10.1053/j.ajkd.2018.12.011. [Epub ahead of print]

PMID:
30738630
11.

Dose distribution verification in high-dose-rate brachytherapy using a highly sensitive normoxic N-vinylpyrrolidone polymer gel dosimeter.

Watanabe Y, Mizukami S, Eguchi K, Maeyama T, Hayashi SI, Muraishi H, Terazaki T, Gomi T.

Phys Med. 2019 Jan;57:72-79. doi: 10.1016/j.ejmp.2018.12.007. Epub 2018 Dec 26.

PMID:
30738535
12.

A modified level set algorithm based on point distance shape constraint for lesion and organ segmentation.

Li X, Li C, Liu H, Yang X.

Phys Med. 2019 Jan;57:123-136. doi: 10.1016/j.ejmp.2018.12.032. Epub 2019 Jan 5.

PMID:
30738516

Supplemental Content

Loading ...
Support Center